Unbiased AI-powered news
SpaceX filed paperwork for a U.S. stock-market debut under ticker SPCX. The planned offering could value the company above $1 trillion and push Elon Musk's net worth past that mark.
news.google.comU.S. markets that would list the company under the ticker SPCX. 25 trillion, and Musk's majority stake could be worth more than $600 billion. 9 billion. 3 billion. 5 billion in debt.
SpaceX flagged more than $500 million in expected legal costs tied to ongoing lawsuits. The cases include allegations that the Grok chatbot created by xAI generated sexualized deepfakes, patent disputes, EU content-moderation claims, music copyright issues, and data-breach complaints.
The filing also disclosed terms of a recent agreement under which Anthropic will pay $15 billion annually to use data centers in the American South for xAI operations.
The IPO filing came days after a jury rejected Musk's lawsuit against OpenAI and its chief executive Sam Altman. The court found the claims were filed after the allowed timeframe. Musk has stated he plans to fold xAI into SpaceX and continue AI work under the larger company.
SpaceX also owns the social-media platform X, which Musk acquired in 2022. " — Ruth Foxe-Blader, managing partner at Citrine Venture Partners SpaceX's Starship rocket is scheduled for a launch this week. The company has faced separate scrutiny over worker safety at its facilities.
These outlets didn't split into competing frames — coverage was uniform.
New ScientistWestern Europe's first total solar eclipse since 1999 will occur on August 12 with totality visible in eastern Greenland, western Iceland and northern Spain. The peak of the Perseid meteor shower will follow hours later under new-moon conditions.
upi.comThe Food and Drug Administration approved enlicitide, sold as Lipfendra, on Thursday. Manufactured by Merck, the pill inhibits PCSK9 and cut LDL levels by up to 60 percent in a 24-week trial of 2,912 participants. It carries a list price of $315 for a 30-day supply and will reach…
flipboard.comEli Lilly will pay $2.8 billion in cash to acquire AtaiBeckley, a developer of psychedelic treatments for mental health conditions. The deal includes up to $1 billion in additional milestone payments. It adds the target’s compounds to Lilly’s neuroscience programs.